Drug Approval | May 19, 2026
Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug
Baxfendy works in a fundamentally different way from current therapies
Baxfendy works in a fundamentally different way from current therapies
Union Minister Prataprao Jadhav terms hypertension a “silent killer”; experts push for early screening, lifestyle correction and wellness-focused healthcare
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
Consensus calls for nationwide adoption of potassium-enriched salt to reduce cardiovascular disease risk
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
Here's a development that aims to keep your blood pressure in check. Literally!
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The medicine was well tolerated, with no unexpected safety issue
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
